| Literature DB >> 32023549 |
Yukun Zhang1, Changyuan Wang1, Jiawei Lu1, Yue Jin1, Canyao Xu1, Qiang Meng1, Qi Liu1, Deshi Dong1, Xiaodong Ma1, Kexin Liu1, Huijun Sun1.
Abstract
Hepatic steatosis and oxidative stress are considered to be the sequential steps in the development ofEntities:
Keywords: NAFLD; catalpol; hepatic steatosis; microRNA; oxidative stress
Year: 2020 PMID: 32023549 PMCID: PMC7041734 DOI: 10.18632/aging.102721
Source DB: PubMed Journal: Aging (Albany NY) ISSN: 1945-4589 Impact factor: 5.682
Figure 1Catalpol ameliorated hepatic steatosis in LDLr-/- mice. The mice were fed with normal or western diet for 16-week, and then sacrificed for morphological and pathological observation. (A) Representative morphological images of liver sections. (B) H&E- stained sections of liver sections. H&E-stained sections were photographed at 200× magnification. (C) Transmission electron microscopy of liver sections. The liver sections were photographed at 10 000× magnification. The lipid droplets were indicated by arrows. ND: normal diet; WD: western diet.
Figure 2Catalpol ameliorated liver index, hepatic injury in LDLr-/- mice. (A) Body weights variation during 16 weeks period. (B) Liver index. (C) Serum levels of ALT and AST. (D) Serum levels of TC, TG. The results are the mean ± SD (n=10), **P< 0.05 vs. Control group, ##P < 0.05 vs. WD group. ND: normal diet; WD: western diet.
Figure 3Catalpol inhibited oxidative stress, promoted ATP production and inhibited hepatic apoptosis. (A) SOD level. (B) MDA level. (C) CAT level. (D) ATP content. (E) ATPase activity. (F) 8-OHdG level. The results are the mean± SD (n=10), **P< 0.05 vs. Control group, ##P < 0.05 vs. WD group. (G) Tunel staining for hepatic apoptosis. Tunel stained sections were photographed at 200× magnification. ND: normal diet; WD: western diet.
Figure 4Potential role of P66Shc in NAFLD. (A) Differentially expressed genes retrieved from ‘GSE94754’ in the GEO dataset. (B) Heat map of differentially expressed genes retrieved from ‘GSE94754’ in the GEO dataset.
Figure 5P66shc was involved in catalpol-mediated protective effects. (A) P66shc protein expression in NAFLD mice. (B) Cytochrome C (Cyto C) protein expression in NAFLD mice. (C) P66shc protein expression in PA- treated hepG2 cells. (D) Cyto C protein expression in PA-treated hepG2 cells. (E) P66shc protein expression was down-regulated by its specific siRNA. (F) JC-1 staining. (G) ROS level. (H) Nile red staining. (I) Tunel staining (Tunel positive cells were stained in green; DAPI was stained to show nuclei). The results are the mean± SD (n=10), **P< 0.05 vs. Control group, ##P < 0.05 vs. WD or PA group.
Changes of the putative p66shc-targeting miRNAs in NAFLD.
| miR-9-5p | 2.69±0.61** |
| miR-96-5p | 0.23±0.04** |
| miR-124-3p | 3.04±0.40** |
N=6,**p<0.05.
NAFLD, Nonalcoholic fatty liver disease; miRNA, microRNA.
Figure 6miR-96-5p regulated p66shc expression in hepG2 cells. HepG2 cells were transfected with ago-96-5p to upregulate miR-96-5p expression. Ago-NC was used as a normal control. (A, B) Argonaute-2 (Ago2) – immunoprecipitated miR-96-5p expression in NAFLD mice and PA-treated hepG2 cells. (C) miR-96-5p expression. (D, E) P66shc and cyto C protein expressions. (F) P66shc mRNA expression. (G) Schematic of the wild-type p66shc 3′UTR (3′UTR-wt) and mutated p66shc 3′UTR (3′UTR-mut) luciferase constructs. (H) HepG2 cells were transfected with 3′UTR-wt or 3UTR-mut and with ago-96-5p or ago-NC, as indicated. **P< 0.05. Error bars depict the standard deviation. BS: binding site; NC: negative control.
Figure 7Catalpol ameliorated oxidative stress, hepatic steatosis and apoptosis through upregulating miR-96-5p. (A) miR-96-5p level. (B) P66Shc protein expression. (C) Cyto C protein expression. (D) ROS level. (E) Nile red staining. (F) JC-1 level. (G) Tunel staining. The results are the mean ± SD (n=8), **P< 0.05 vs. Control group, ##P < 0.05 vs. WD group.
Figure 8Graphic summary for the mechanism that catalpol ameliorates NAFLD through upregulating miR-96-5p level via p66shc/cytochrome C cascade.